公开(公告)号：US20220112214A1

公开(公告)日：2022-04-14

申请号：US17274990

申请日：2019-09-06

申请人： ARRAY BIOPHARMA INC.

发明人： James F. BLAKE ,  Donghua DAI ,  Julia HAAS ,  Yutong JIANG ,  Dean KAHN ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Andrew T. METCALF ,  David A. MORENO ,  Brett PRIGARO ,  Ginelle A. RAMANN ,  Li REN ,  Shane M. WALLS ,  Hailong ZHANG

IPC分类号： C07D498/22 ,  C07D513/22 ,  C07D498/14 ,  A61K45/06 ,  A61K31/554 ,  A61K31/55 ,  A61K31/519 ,  C07D487/14 ,  A61P35/00

摘要： Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20220313676A1

公开(公告)日：2022-10-06

申请号：US17108528

申请日：2020-12-01

申请人： Array Biopharma Inc.

发明人： Steven W. ANDREWS ,  Sean ARONOW ,  James F. BLAKE ,  Barbara J. BRANDHUBER ,  James COLLIER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Ginelle A. RAMANN ,  Tony P. TANG ,  Li REN ,  Shane M. WALLS

IPC分类号： A61K31/4545 ,  A61K31/4162 ,  C07D471/04 ,  A61P1/00 ,  A61P35/00 ,  A61P35/02 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P1/12

摘要： Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20220119396A1

公开(公告)日：2022-04-21

申请号：US17514684

申请日：2021-10-29

申请人： Array BioPharma Inc.

发明人： Steven W. ANDREWS ,  James F. BLAKE ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  David A. MORENO ,  Li REN ,  Shane M. WALLS

IPC分类号： C07D487/04

摘要： Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

公开(公告)号：US20200030311A1

公开(公告)日：2020-01-30

申请号：US16579150

申请日：2019-09-23

申请人： Array Biopharma Inc.

发明人： Steven W. ANDREWS ,  Sean ARONOW ,  James F. BLAKE ,  Barbara J. BRANDHUBER ,  James COLLIER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. McFADDIN ,  Megan L. McKENNEY ,  Oren T. McNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Ginelle A. RAMANN ,  Tony P. TANG ,  Li REN ,  Shane M. WALLS

IPC分类号： A61K31/4545 ,  A61K31/4162 ,  C07D471/04 ,  A61P1/00 ,  A61P35/00 ,  A61P35/02 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P1/12

摘要： Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20220081438A1

公开(公告)日：2022-03-17

申请号：US17416117

申请日：2019-12-13

申请人： ARRAY BIOPHARMA INC.

发明人： James F. Blake ,  David A. MORENO ,  Li REN ,  Tony P. TANG ,  Shane M. WALLS

IPC分类号： C07D471/04 ,  C07D519/00

摘要： Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

公开(公告)号：US20200339579A1

公开(公告)日：2020-10-29

申请号：US16962305

申请日：2019-01-18

申请人： Array BioPharma Inc.

发明人： Shane M. WALLS ,  LI REN ,  Ginelle A. RAMANN ,  David A. MORENO ,  Andrew T. METCALF ,  Elizabeth A. MCFADDIN ,  Gabrielle R. KOLAKOWSKI ,  James F. BLAKE ,  Donghua DAI ,  Julia HAAS ,  Yutong JIANG ,  Dean KAHN

IPC分类号： C07D471/04 ,  C07F9/6561

摘要： Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.